Chardan Capital Maintains Buy on Avidity Biosciences, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a 'Buy' rating on Avidity Biosciences (NASDAQ:RNA) but has lowered the price target from $27 to $23.
August 09, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital maintains a 'Buy' rating on Avidity Biosciences but lowers the price target from $27 to $23.
The news is directly related to Avidity Biosciences. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100